

# The importance of genomic studies in Indonesian population

**Beben Benyamin**

**beben.benyamin@unisa.edu.au**

**Australian Centre for Precision Health &  
Allied Health and Human Performance**

**Adelaide, 14 October 2020**



- I am senior lecturer in biostatistics (I teach statistics, genetics, epidemiology and public health)
- I research statistical genetic and epidemiology of complex diseases and trait
- <https://people.unisa.edu.au/Beben.Benyamin>
- <https://scholar.google.com.au/citations?user=wMoqGWQAAA&hl=en>

# Menyongsong Kedokteran Presisi dengan Genom Indonesia



**BEBEN BENYAMIN**

Dosen Senior dan Peneliti di Bidang Genetika Statistik, University of South Australia, Adelaide

**J**ago. Julukan itu diberikan kepada Rohani, kakek 80 tahun dari suku Bajo, Pulau Toge (Sulawesi), karena ketangguhannya menyelam. Seperti kebanyakan lelaki Bajo, Rohani bisa menyelam untuk berburu ikan dan hewan laut lainnya sampai kedalaman 70 meter selama beberapa menit. Unikinya, semua itu dilakukan tanpa menggunakan alat penyelam. Bermodal kacamata berbingkai kayu, kemampuan menyelam orang Bajo di luar batas kemampuan manusia biasa. Kisah hidup Rohani diang-

logi sekuensing atau pengejaan huruf DNA canggih, berbagai penelitian berbasis genom diharapkan bisa dilakukan di Indonesia, baik secara mandiri maupun kolaborasi. Selama ini mayoritas penelitian tentang asal-usul manusia Indonesia dan penelitian kedokteran berbasis genom Indonesia mengemuka, misalnya satu gen atau satu kromosom Y saja. Dengan teknologi yang baru diresmikan, sekarang penelitian dapat dilakukan pada seluruh bagian genom yang memuat sekitar 20.000 gen. Gen sendiri merupakan unit kecil dari genom yang memberikan instruksi pembuatan protein.

Di dunia tonggak penelitian genom manusia sendiri sebenarnya dimulai seperempat abad lalu dengan dibentuknya *Human Genome Project*. Proyek sains raksasa yang menghabiskan USD3 miliar ini bertujuan memetakan 3 miliar huruf DNA penyusun ge-

nom yang mempengaruhi penyakit tersebut telah diidentifikasi. Teknik ini dikenal dengan sebutan *genome-wide association study* (GWAS).

Berbagai penyakit dan karakteristik yang bisa diamati tidak luput dari penelitian. Ilmuwan tidak hanya meneliti kondisi yang sering kita sebut sebagai penyakit "genetik" saja, seperti talasemia atau hemofilia. Sekarang hampir semua penyakit dan karakteristik yang selama ini dianggap tidak banyak dipengaruhi genetik pun tak luput dari penelitian GWAS. Dari rambut ikal sampai tangan kidal. Dari asma sampai skizofrenia. Semua dicari gen penyebabnya.

Walaupun sulit, laksana mencari jarum ditumpukan jerami, buah dari proyek raksasa ini sudah mulai bisa dipetik. Ribuan perubahan huruf DNA telah berhasil dikaitkan dengan berbagai penyakit dan karakteristik manusia. Sebagian temuan

suku Bajo bisa menyelam sangat dalam dan lama tanpa menggunakan alat penyelam?

Mereka memulai dengan membandingkan ukuran limpa orang Bajo dengan orang Saluan. Suku Saluan dijadikan sebagai pembanding karena letaknya berdekatan, tapi tidak mempunyai tradisi menyelam seperti suku Bajo. Ukuran limpa diteliti karena pada mamalia penyelam andal seperti anjing laut, ukuran limpanya lebih besar daripada proporsi bagian tu-



nomnya sudah banyak dipelajari. Ternyata mereka menemukan bahwa variasi pada gen *PDE10A* dan *BDKRB2* di suku Bajo terseleksi secara turun-temurun. Proses seleksi ini diperkirakan berlangsung selama ribuan tahun.

Dari analisa lanjutan, mereka juga berhasil membuktikan bahwa variasi di dua gen tersebut berkorelasi positif dengan ukuran limpa (*PDE10A*) dan sifat refleks menyelam (*BDKRB2*). Penelitian seperti ini menjawab kenapa suatu suku mempunyai karakteristik dibanding orang kebanyakan. Tak kalah penting, penelitian seperti ini juga bisa membawa dampak pada penelitian kedokteran. Penelitian tentang kemampuan menyelam suku Bajo bisa membuka penelitian baru tentang hipoksia, kondisi berkurangnya oksigen dalam tubuh.

## Keunikan Lain

## Kedokteran Presisi dengan Genom Indonesia

Dalam satu dekade terakhir, dunia sedang bergerak menuju praktik kedokteran masa depan. Praktik kedokteran karena keunikan pasien, baik dari segi genom, lingkungan, maupun gaya hidupnya, dijadikan acuan perawatan. Kalau selama ini boleh dibayangkan bahwa pengobatan disamaratakan bagi setiap pasien, di era *precision medicine* (kedokteran presisi) praktik tersebut akan menjadi masalah.

Sampai saat ini mayoritas (80%) penelitian genom menggunakan sampel dari orang keturunan Eropa. Hanya 20% menggunakan sampel dari belahan dunia lain, termasuk Afrika, Asia, dan Amerika Latin. Sedangkan penggunaan sampel dari Indonesia untuk penelitian genom mutakhir, terutama di bidang kedokteran, masih terbatas. Bahkan, dibanding dengan negara-negara te-

pemimpinan ilmuwan Indonesia dalam bidang ini sangat menentukan. Penggunaan sampel genom Indonesia untuk mengatasi masalah-masalah kedokteran di Indonesia tidak bisa ditunda-tunda lagi. Kita tidak bisa hanya mengandalkan hasil penelitian genom Eropa atau negara lain.

Untuk itu, adanya dukungan pemerintah dengan dibentuknya Pusat Genom Nasional merupakan angin segar perlu diapresiasi. Tapi tentu saja jangan berhenti di sana. Kita ketahui bahwa penelitian genom memakan biaya yang mahal. Karena itu, dukungan dana penelitian yang besar dengan durasi panjang dan berkelanjutan menjadi keharusan. Pelatihan-pelatihan bidang genom untuk memperkuat sumber daya manusianya juga perlu segera ditingkatkan.


Selain itu, sudah saatnya Indonesia membentuk Biobank Indonesia. Biobank ini ditujukan untuk menjadi pusat ko-

[http://koran-sindo.com/page/news/2018-05-22/1/0/Menyongsong\\_Kedokteran\\_Presisi\\_dengan\\_Genom\\_Indonesia](http://koran-sindo.com/page/news/2018-05-22/1/0/Menyongsong_Kedokteran_Presisi_dengan_Genom_Indonesia)


# Mendelian disease

vs

# Complex disease




Cystic fibrosis, Huntington's disease



Schizophrenia, type 2 diabetes


# My research questions



1. What causes this phenotypic variation?
  - What are the relative contribution of genetic and environmental factors on complex trait or disease?
2. How do we find genes affecting individual differences?
3. How do we use this genomic information in medicine?



# Goal: Precision (personalized) medicine

Figure 2: Precision medicine builds on participation from the population. An individual has their genomic and environmental health data collected. This is analysed against population-wide records, allowing doctors to identify preventative treatments customised to benefit each individual.



- 1. What are the relative contribution of genetic and environmental factors on complex disease?**
2. How do we find genes affecting complex disease?
3. How do we use this genomic information in medicine?

# How do we estimate the genetic contribution to complex traits?



**Heritability: Proportion of phenotypic variance explained by genetic factors.**


$$\text{Heritability } (h^2) = 2 * (r_{MZ} - r_{DZ}) \sim 80\%$$



# Meta-analysis of all twin studies in the last 50 years

**2,748 papers**, published between 1958 and 2012,  
reporting on **17,804 traits** on a total of **14,558,903 twin pairs**

- The average heritability of all human traits is 49%.
- Common environmental variance contribute to a 17% of the phenotypic variance.





Meta-analysis of the heritability of human traits based on fifty years of twin studies


Tinca J C Polderman<sup>1,10</sup>, Beben Benyamin<sup>2,10</sup>, Christiaan A de Leeuw<sup>1,3</sup>, Patrick F Sullivan<sup>4-6</sup>, Arjen van Bochoven<sup>7</sup>, Peter M Visscher<sup>2,8,11</sup> & Danielle Posthuma<sup>1,9,11</sup> <sup>10</sup>These authors contributed equally

1. What are the relative contribution of genetic and environmental factors on complex disease?
2. How do we find genes affecting complex disease?
3. How do we use this genomic information in medicine?



# Genome-wide Association Study (GWAS)



[www.genomicseducation.hee.nhs.uk](http://www.genomicseducation.hee.nhs.uk)



# Challenges: Most studies are of European ancestry: Can the findings be transferred into other populations?



1000Genome Project 2015

- Lactose intolerant in different populations due to mutations in *LCT* gene.
- Strength of association can be different between populations (*MHC* gene for schizophrenia).
- South East Asian populations homes to a half billion people are not well represented.

Martin et al Nat Gen,2019

# Differences in drug response between ethnic groups

Drug <sup>A</sup>	Therapeutic Area <sup>A</sup>	Referenced Subgroup <sup>A</sup>	Prevalence
Codeine	Anesthesiology	<i>CYP2D6</i> Ultra-rapid metabolizers	more common in Caucasians (1-10%) and less in Chinese and Japanese (0.5-1%) <sup>B</sup> .
Warfarin	Cardiology or Hematology	<i>VKORC1</i> A allele carriers (e.g., -1639G>A)	Allele frequencies for AA genotype (lower warfarin dose requirement): 14.2% in Caucasians versus 82.1% in Chinese [2].
Amitriptyline	Psychiatry	<i>CYP2D6</i> poor metabolizers	~6-10% in Caucasians vs ~2% in Asians[1]
Clopidogrel	Cardiology	<i>CYP2C19</i> poor metabolizers	poor metabolizers: 3-5% in Caucasian vs 15-20% in Asians[3]
Carbamazepine	Neurology	<i>HLA-B*1502</i> allele carriers	>15% in Hong Kong, about 10% in Taiwan, but largely absent (0-1%) in Caucasians <sup>C</sup> .
Erlotinib	Oncology	<i>EGFR</i> exon 19 deletion or exon 21 substitution (L858R) positive	<i>EGFR</i> activating mutation frequencies: ~ 50-60% of NSCLC in Asia-Pacific versus only 12-13% in UK [5].
Irinotecan	Oncology	<i>UGT1A1*28</i> allele carriers	Allele frequencies for <i>UGT1A1</i> 7/7 genotype (high incidence of neutropenia) is 12-13% in Caucasians, 23% in Blacks and lower (2-8%) in Asians [2,12].

<sup>A</sup>AS in FDA; Table of pharmacogenomic biomarkers in drug labeling (<http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm>);

<sup>B</sup>FDA NDA 206323 from [www.accessdata.fda.gov/scripts/cder/daf/index.cfm](http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm);


<sup>C</sup>FDA NDA 016608 from [www.accessdata.fda.gov/scripts/cder/daf/index.cfm](http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm).

Epilepsy drug – > Steven Johnsons Syndrome

**Table 1:** Examples of drugs exhibiting ethnic differences in pharmacogenomic variants.

# Answers: Genomic studies using Indonesian and Chinese samples

- Trans-ethnic genomic and epigenomic studies of motor neuron disease using samples from China (1,300 cases and 3,000 controls) combined with European samples (12,000 cases and 23,000 controls).
- We found genes affecting motor neuron diseases (*GPX3-TNIP1*)



ARTICLE

DOI: 10.1038/s41467-017-00471-1 OPEN

Cross-ethnic meta-analysis identifies association of the *GPX3-TNIP1* locus with amyotrophic lateral sclerosis

Beben Benyamin et al.<sup>#</sup>



www.nature.com/npjgenmed

ARTICLE OPEN

Significant out-of-sample classification from methylation profile scoring for amyotrophic lateral sclerosis

Marta F. Nabais<sup>1,2</sup>, Tian Lin<sup>1</sup>, Beben Benyamin<sup>1,3</sup>, Kelly L. Williams<sup>4</sup>, Fleur C. Garton<sup>1</sup>, Anna A. E. Vinkhuyzen<sup>1</sup>, Futao Zhang<sup>1</sup>, Costanza L. Vallergera<sup>1</sup>, Restuadi Restuadi<sup>1</sup>, Anna Freydenzon<sup>1</sup>, Ramona A. J. Zwamborn<sup>5</sup>, Paul J. Hop<sup>5</sup>, Matthew R. Robinson<sup>1</sup>, Jacob Gratten<sup>1,6</sup>, Peter M. Visscher<sup>1,7</sup>, Ellis Hannon<sup>8</sup>, Jonathan Mill<sup>2,8</sup>, Matthew A. Brown<sup>9</sup>, Nigel G. Laing<sup>10,11</sup>, Karen A. Mather<sup>12,13</sup>, Perminder S. Sachdev<sup>12,14</sup>, Shyuan T. Ngo<sup>7,15,16</sup>, Frederik J. Steyn<sup>15,16</sup>, Leanne Wallace<sup>17</sup>, Anjali K. Henders<sup>1</sup>, Merrilee Needham<sup>17,18,19</sup>, Jan H. Veldink<sup>3</sup>, Susan Mathers<sup>20</sup>, Garth Nicholson<sup>21</sup>, Dominic B. Rowe<sup>16</sup>, Robert D. Henderson<sup>7,16,22</sup>, Pamela A. McCombe<sup>16,22</sup>, Roger Pamphlett<sup>23</sup>, Jian Yang<sup>17,24</sup>, Ian P. Blair<sup>4,24</sup>, Allan F. McRae<sup>1,7,24</sup> and Naomi R. Wray<sup>1,7,24\*</sup>

Molecular Genetics & Genomic Medicine

Open Access

ORIGINAL ARTICLE

Whole exome sequencing and DNA methylation analysis in a clinical amyotrophic lateral sclerosis cohort

Fleur C. Garton<sup>1,2</sup>, Beben Benyamin<sup>1,2</sup>, Qiongyi Zhao<sup>1</sup>, Zhijun Liu<sup>1,2</sup>, Jacob Gratten<sup>1,2</sup>, Anjali K. Henders<sup>1,2</sup>, Zong-Hong Zhang<sup>1</sup>, Janette Edson<sup>1</sup>, Sarah Furlong<sup>1</sup>, Sarah Morgan<sup>3,4</sup>, Susan Heggie<sup>5</sup>, Kathryn Thorpe<sup>5</sup>, Casey Pfluger<sup>5</sup>, Karen A. Mather<sup>6</sup>, Perminder S. Sachdev<sup>6,7</sup>, Allan F. McRae<sup>1,2</sup>, Matthew R. Robinson<sup>1,2</sup>, Sonia Shah<sup>1</sup>, Peter M. Visscher<sup>1,2,8</sup>, Marie Mangelsdorf<sup>1</sup>, Robert D. Henderson<sup>3</sup>, Naomi R. Wray<sup>1,2,\*</sup> & Pamela A. McCombe<sup>5,\*</sup>

Whole-exome sequencing in amyotrophic lateral sclerosis suggests *NEK1* is a risk gene in Chinese

Jacob Gratten<sup>1,2</sup>, Qiongyi Zhao<sup>1</sup>, Beben Benyamin<sup>1,2</sup>, Fleur Garton<sup>1,2</sup>, Ji He<sup>3</sup>, Paul J. Leo<sup>4,5</sup>, Marie Mangelsdorf<sup>1</sup>, Lisa Anderson<sup>4,5</sup>, Zong-Hong Zhang<sup>1</sup>, Lu Chen<sup>3</sup>, Xiang-Ding Chen<sup>6</sup>, Katie Cremin<sup>4,5</sup>, Hong-Weng Deng<sup>7</sup>, Janette Edson<sup>1</sup>, Ying-Ying Han<sup>8</sup>, Jessica Harris<sup>4,5</sup>, Anjali K. Henders<sup>1,2</sup>, Zi-Bing Jin<sup>9</sup>, Zhongshan Li<sup>10</sup>, Yong Lin<sup>8</sup>, Xiaolu Liu<sup>3</sup>, Mhairi Marshall<sup>4,5</sup>, Bryan J. Mowry<sup>1,13</sup>, Shu Ran<sup>8</sup>, David C. Reutens<sup>11</sup>, Sharon Song<sup>4,5</sup>, Li-Jun Tan<sup>6</sup>, Lu Tang<sup>3</sup>, Robyn H. Wallace<sup>1</sup>, Lawrie Wheeler<sup>4,5</sup>, Jinyu Wu<sup>10</sup>, Jian Yang<sup>1,2</sup>, Hui Xu<sup>12</sup>, Peter M. Visscher<sup>1,2</sup>, Perry F. Bartlett<sup>1</sup>, Matthew A. Brown<sup>4,5</sup>, Naomi R. Wray<sup>1,2\*</sup> and Dongsheng Fan<sup>3</sup>

# Answers: Genomic studies using Indonesian and Chinese samples

- 23K cases and 35K controls from East Asian populations (including 2000 cases/controls from Indonesia) – 19 loci
- Genetic correlation between EAS and EUR ( $r_G = 0.98 \pm 0.03$ )
- MHC locus, the strongest signal in EUR was not significant in EAS. This reflects the complexity of MHC region (linkage disequilibrium) and limited power in EAS (MHC MAF is lower in EAS)

Association of rs1344706 in the ZNF804A gene with schizophrenia in a case/control sample from Indonesia

Sibylle G. Schwab <sup>a,\*</sup>, Agung A.A. Kusumawardhani <sup>b</sup>, Nan Dai <sup>c,d</sup>, WenWen Qin <sup>c,d</sup>, Mutiara D.B. Wildenauer <sup>c,d</sup>, Feranindhya Agjananda <sup>b</sup>, Nurmiati Amir <sup>b</sup>, Ronald Antoni <sup>b</sup>, Tiana Arsianti <sup>b</sup>, Asmarahadi Asmarahadi <sup>b</sup>, Hervita Diatri <sup>b</sup>, Prianto Djatmiko <sup>b</sup>, Irmansyah Irmansyah <sup>b</sup>, Siti Khalimah <sup>b</sup>, Irmia Kusumadewi <sup>b</sup>, Profitasari Kusumaningrum <sup>b</sup>, Petrin R. Lukman <sup>b</sup>, Lukman Mustar <sup>b</sup>, Martina W. Nasrun <sup>b</sup>, Safyuni Naswati <sup>b</sup>, Prasetyawan Prasetyawan <sup>b</sup>, Gerald M. Semen <sup>b</sup>, Kristiana Siste <sup>b</sup>, Heriani Tobing <sup>b</sup>, Natalia Widiasih <sup>b</sup>, Tjhin Wiguna <sup>b</sup>, Widayanti Dewi Wulandari <sup>b</sup>, Indonesian Schizophrenia Genetics Consortium <sup>1</sup>, Beben Benyamin <sup>e</sup>, Dieter B. Wildenauer <sup>c,d,f</sup>



## Comparative genetic architectures of schizophrenia in East Asian and European populations

Max Lam <sup>1,2,3,4,5,6,7,2</sup>, Chia-Yen Chen <sup>4,5,7,8,9,7,2</sup>, Zhiqiang Li <sup>10,11</sup>, Alicia R. Martin <sup>4,5,7</sup>, Julien Bryois <sup>12</sup>, Xixian Ma <sup>13</sup>, Helena Gaspar <sup>14</sup>, Masashi Ikeda <sup>15</sup>, Beben Benyamin <sup>16,17,18</sup>, Brielin C. Brown <sup>19,20</sup>, Ruize Liu <sup>4,5</sup>, Wei Zhou <sup>11,21</sup>, Lili Guan <sup>22,23,24</sup>, Yoichiro Kamatani <sup>25,26</sup>, Sung-Wan Kim <sup>27</sup>, Michiaki Kubo <sup>28</sup>, Agung A. A. Kusumawardhani <sup>29</sup>, Chih-Min Liu <sup>30,31</sup>, Hong Ma <sup>22,23,24</sup>, Sathish Periyasamy <sup>32,33</sup>, Atsushi Takahashi <sup>26,34</sup>, Zhida Xu <sup>35</sup>, Hao Yu <sup>22,23,24</sup>, Feng Zhu <sup>36,37,38</sup>, Schizophrenia Working Group of the Psychiatric Genomics Consortium <sup>39</sup>, Indonesia Schizophrenia Consortium <sup>39</sup>, Genetic REsearch on schizopreniA neTwork-China and the Netherlands (GREAT-CN) <sup>39</sup>, Wei J. Chen <sup>30,31,40</sup>, Stephen Faraone <sup>41</sup>, Stephen J. Glatt <sup>42</sup>, Lin He <sup>11,43,44</sup>, Steven E. Hyman <sup>5,45</sup>, Hai-Gwo Hwu <sup>30,31,40</sup>, Steven A. McCarrroll <sup>5,46</sup>, Benjamin M. Neale <sup>4,5,7</sup>, Pamela Sklar <sup>47</sup>, Dieter B. Wildenauer <sup>48</sup>, Xin Yu <sup>22,23,24</sup>, Dai Zhang <sup>22,23,24</sup>, Bryan J. Mowry <sup>32,33</sup>, Jimmy Lee <sup>49</sup>, Peter Holmans <sup>50</sup>, Shuhua Xu <sup>13,51,52,53</sup>, Patrick F. Sullivan <sup>54</sup>, Stephan Ripke <sup>4,5,55</sup>, Michael C. O'Donovan <sup>50</sup>, Mark J. Daly <sup>4,5,7,56</sup>, Shengying Qin <sup>11,57,71</sup>, Pak Sham <sup>58,59,71</sup>, Nakao Iwata <sup>15,71</sup>, Kyung S. Hong <sup>60,71</sup>, Sibylle G. Schwab <sup>61,62,71</sup>, Weihua Yue <sup>22,23,24,63,71\*</sup>, Ming Tsuang <sup>64,71\*</sup>, Jianjun Liu <sup>2,65,71\*</sup>, Xiancang Ma <sup>37,38,66,71\*</sup>, René S. Kahn <sup>67,68,69,71\*</sup>, Yongyong Shi <sup>11,10,11,70,71\*</sup> and Hailiang Huang <sup>4,5,7,71\*</sup>

medRxiv THE PREPRINT SERVER FOR HEALTH SCIENCES

CSH Cole Spring Institute Laboratory BMJ Yale

HOME | ABC

Search

Comment on this paper

Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia

Schizophrenia Working Group of the Psychiatric Genomics Consortium, Stephan Ripke, James TR Walters, Michael C O'Donovan

doi: <https://doi.org/10.1101/2020.09.12.20192922>

# Challenges and opportunities

- The explosion of big data in genomics (and new omics data) combined with health records (biobanks).
  - How can we make sense this complexity?
  - How can we analyze this data efficiently?
  - How can we use this data in precision health?
- A half of billion of people is South East Asians (half of them are Indonesians), but they are not well represented in this genomic revolution.
  - How can we intensify the collaboration with scientists from this region to participate in this genomic revolution?



# Australian Centre for Precision Health

## About us

Australian Centre for Precision Health (ACPreH) is part of the University of South Australia Cancer Research Institute. We are based at the South Australian Health and Medical Research Institute, with a genotyping facility at University of South Australia City East campus. We are active researchers, with many of us also involved in teaching UniSA health sciences, medical science and pharmacy-based degrees.



**Our people**



**Mission**

# Australian Centre for Precision Health

<https://www.unisa.edu.au/research/cri/our-research/australian-centre-for-precision-health/>

## Population Health

Epidemiological analyses, including cancer, nutritional, genetic, lifecourse, spatial and social epidemiology.

Predicting risk and identifying determinant's of disease and strategies for prevention

Medical statistics, longitudinal modelling

Data linkage, big data

## Genomics

Genetic and phenotypic risk prediction modelling

Gene-environment interaction

Establishing causality, and predicting the totality of risk (phenomewide analyses, Mendelian randomization)

Large scale genomics analyses, including gene discovery

## Translation

Informing appropriateness of care and patient safety

Cancer screening; developing cancer monitoring systems

Increasing survival, preventing disease and improving care.

Informing cost effectiveness and social policy

Developing E-health (iHealth) applications

**Benefit to population:** accurate and evidence based disease prediction, prevention and care

**Prevention with precision:** identifying and overcoming individual vulnerabilities

**Data to health:** using advanced statistical methods to turn big data to knowledge

**Collaboration for impact:** Listening to people, contributing to policy and global research consortia



# Research Opportunities (Masters, PhD, Collaboration)

*Dr Beben Benyamin*

*Australian Centre for Precision Health, University of South Australia  
(<http://u.unisa.edu.au/research/cpi/our-research/australian-centre-for-precision-health/>)*

## Background:

- We differ in a range of characteristics/traits and our susceptibility to disease also varies.
- These differences are caused by genetic and environmental factors (and their interactions)
- Understanding these factors are important and useful in psychology, medicine and other fields

## Broad aims:



- To understand the genetic and environmental causes underpinning individual difference neuropsychiatric traits/diseases
- To identify underlying genetic variation affecting neuropsychiatric traits/diseases
- To use these genomic and other omics information in **precision medicine** (e.g. disease prediction, tailored treatment, drug development)

## Approaches:

- Using advanced computing and statistical methods applied to genomics and other omics (e.g. epigenomics, transcriptomics) combined with phenotypic and clinical data
- Data obtained through collaborations with other researchers and clinicians as well as sourced from publicly available resources, such as UK Biobank (500,000 individuals)

## Available projects:

- Integrative genomic and epigenomic analyses to dissect neurodegenerative diseases, such as motor neuron disease
- Trans-ethnic genomic analysis for neuropsychiatric diseases, such as schizophrenia in European and Asian populations
- Inferring the causal effects of risk factors, such as sleep or exercise on disease



# Acknowledgment

## University of South Australia:

Prof Elina Hypponen  
Dr Ang Zhou

## QIMR Berghofer:

Prof Nick Martin  
Dr John Whitfield

## University of Wollongong:

A/Prof Sibylle Schwab

## University of Queensland:

Prof Peter Visscher  
Prof Naomi Wray  
Dr Fleur Garton

## Peking University:

Prof Dongsheng Fan  
Dr Ji He

## University of Indonesia/RSCM:

Dr AAA Agung Kusumawardhani

## University of Western Australia:

Prof Dieter Wildenauer

## Harvard University:

Dr Hailiang Huang



# Terima Kasih!

- If you are interested to do Masters/PhD study or research collaboration, please contact me at:  
[beben.benyamin@unisa.edu.au](mailto:beben.benyamin@unisa.edu.au)

